Author: Ravi Shankar

Independent NCAT findings demonstrate comparable pavement performance under approximately 8 million equivalent single-axle loads, while eliminating lime treatment and substantially reducing conventional stabilizing materials, and significantly lowering embodied carbon emissions associated with pavement construction

ST. LOUIS, Nov. 11, 2026 (GLOBE NEWSWIRE) — Verde Resources, Inc. (OTCQB: VRDR) (“Verde” or the “Company”), an emerging leader in sustainable infrastructure technologies, today announced encouraging findings from the National Center for Asphalt Technology (NCAT) at Auburn University, demonstrating the potential of TerraZyme®, a proprietary enzyme-based soil stabilizer, to significantly reduce conventional stabilizing materials while maintaining comparable overall pavement performance under accelerated heavy-truck loading.

Presented during NCAT’s September 2026 sponsor meeting, the findings evaluated Verde-sponsored Section S11, constructed in 2024 using TerraZyme®-based enzyme stabilization, against a conventional control section incorporating traditional cement- and lime-based stabilization.

Section S11 demonstrated overall pavement performance comparable to the conventional control section through approximately 8 million equivalent single-axle loads (ESALs), despite eliminating lime treatment from the subgrade and reducing base-layer cement content by approximately 61%. Both sections exhibited similar rutting performance, with no cracking reported during the evaluation period.

These findings mark an important technical milestone in Verde’s efforts to advance commercially viable alternatives to conventional soil stabilization, particularly for infrastructure projects involving challenging soil conditions and significant material requirements.

Section S11 incorporated just 2% cement in its stabilized base, representing an approximately 61% reduction in cement content relative to the conventional control section. Additionally, S11 eliminated conventional lime treatment from the subgrade, instead utilizing TerraZyme® as part of its alternative stabilization approach.

The research also demonstrated the potential to make greater use of locally available soil materials. Section S11 successfully incorporated 25% A-6 clay into its stabilized base, demonstrating the potential to utilize existing soil resources and potentially reduce the need for imported aggregates or extensive soil replacement in suitable applications.

Despite these differences in material composition and stabilization approach, NCAT reported comparable overall pavement performance through approximately 8 million ESALs of accelerated truck loading. While the sections exhibited different structural responses, including higher measured horizontal tensile strain in S11, the findings provide encouraging evidence that TerraZyme®-based stabilization can reduce conventional material requirements while maintaining comparable observed pavement performance.

“For decades, conventional road construction has relied heavily on cement and lime to stabilize challenging soil conditions. These findings demonstrate that there may be a more material-efficient and lower carbon approach,” said Eric Bava, Chief Operating Officer of Verde Resources. “Achieving comparable pavement performance under approximately 8 million ESALs while eliminating lime treatment and reducing base-layer cement usage by more than 60% represents a significant milestone for TerraZyme®. It also addresses a fundamental challenge facing the infrastructure industry: how to build durable roads while reducing material consumption, construction costs, and the carbon footprint of infrastructure development.”

Independent Research Supports Alternative Soil Stabilization
NCAT’s test track provides a controlled research environment where experimental pavement structures are subjected to repeated heavy-truck loading while researchers monitor structural responses, pavement deformation, and field performance.

The S11 research program was designed to evaluate whether enzyme-assisted stabilization could provide a practical alternative to conventional lime- and cement-treated pavement foundations. The findings indicated that, although the stabilized layers exhibited different stiffness characteristics, the asphalt concrete modulus was similar between the evaluated sections, and their overall field performance remained comparable through the evaluated traffic loading.

“The S11 research provides valuable field performance data on an alternative approach to pavement foundation stabilization,” said Nathan Moore, Assistant Director for Test Track Research at NCAT. “What is particularly encouraging is that the enzyme-and-cement-stabilized section demonstrated overall pavement performance comparable to a conventional cement-and-lime-stabilized control section through approximately 8 million ESALs, despite differences in the structural responses of the stabilized layers. These findings contribute to our understanding of alternative stabilization methods and provide an important foundation for continued research and evaluation.”

Expanding Opportunities Across the U.S. Infrastructure Market
The implications of these findings extend beyond NCAT’s test track. Soil stabilization remains an essential component of road construction and rehabilitation, particularly in regions where expansive clay, weak subgrade materials, and challenging soil conditions require substantial chemical treatment or material replacement.

In its September 2026 presentation, NCAT specifically identified Alabama, Arkansas, Mississippi, and Texas among the states facing challenges associated with poor-quality base materials and expansive subgrade soils. Verde believes these conditions present meaningful opportunities to evaluate TerraZyme®-based stabilization as an alternative for road construction, rehabilitation, and other infrastructure applications.

By potentially reducing cement and lime requirements while enabling greater utilization of locally available soil materials, TerraZyme® could offer transportation agencies and infrastructure contractors opportunities to improve construction economics, reduce material transportation requirements, and lower the embodied carbon associated with conventional stabilization practices. These potential benefits remain subject to project-specific engineering validation, cost analysis, and environmental assessment.

“We see TerraZyme® as much more than a soil stabilization product. We see it as a technology with the potential to change how road foundations are engineered, particularly in regions where difficult soil conditions have historically required extensive treatment or material replacement,” added Bava. “With these encouraging findings from NCAT, our focus is now on translating technical validation into commercial opportunities through engagement with state transportation agencies, engineering firms, and infrastructure contractors.”

Advancing Commercialization and Field Applications
Verde intends to build upon the NCAT findings by pursuing additional field evaluations and pilot applications to assess TerraZyme®’s performance across different soil conditions, climates, and construction requirements.

The Company believes that demonstrating both engineering performance and economic competitiveness will be essential to broader adoption. Future evaluations are expected to focus on soil strength, durability, material efficiency, construction costs, and environmental impacts, providing transportation agencies and contractors with the technical information needed to assess TerraZyme® for their respective applications.

TerraZyme® also aligns with Verde’s broader commercialization strategy of integrating sustainable materials and technologies into conventional infrastructure projects while maintaining the fundamental engineering requirements of roads and other transportation assets.

Alongside its engineered biochar applications for asphalt, TerraZyme® represents another component of Verde’s strategy to develop a scalable sustainable infrastructure platform addressing both pavement foundations and surface materials.

“Our vision has always been to make sustainability an integral part of how infrastructure is built, rather than an added cost or consideration,” concluded Bava. “The NCAT results demonstrate the potential of combining material efficiency with engineering performance. Our next priority is taking these findings beyond the test track and into practical, commercially viable applications. We believe TerraZyme® has the potential to create meaningful value for the infrastructure industry while advancing Verde’s broader sustainable infrastructure strategy.”

About Verde Resources, Inc.
Verde Resources, Inc. (OTCQB: VRDR) is an emerging leader in sustainable infrastructure technologies, focused on developing and commercializing engineered biochar solutions for asphalt, road construction, and other applications. Through strategic collaborations, advanced materials science, and independently verified environmental accounting, Verde is advancing its mission to help industries #TransitionToZero®.

Verde has partnered with Nature Plus, Inc. (NPI), the developer and manufacturer of TerraZyme®, to build on NPI’s 30 years of global experience in TerraZyme® -based soil stabilization. This collaboration aims to advance a hybrid technology with significant potential to reduce carbon emissions and construction costs while creating new opportunities for sustainable solutions in traditional road construction and maintenance.

For more information, visit www.verderesources.com.

About NCAT:
NCAT is a world leader in asphalt pavement technology, partnering with the National Asphalt Pavement Association, state transportation departments, the Federal Highway Administration, and industry stakeholders. Globally recognized for research, training, and technology transfer, it focuses on safe, sustainable, and cost-effective pavements.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of Verde’s management made in connection with the matters addressed by this press release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Verde’s expectations, projections, and potential future developments. Statements attributed to Verde reflects its views as of the date hereof and are not intended as guarantees of future performance. All forward-looking statements are subject to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Forward-looking statements involve significant known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially and adversely from those expressed or implied. In some cases, forward-looking statements can be identified by words such as “may,” “will,” “expect,” “plan,” “believe,” “estimate,” “anticipate,” “project,” “seek,” “propose,” “intend,” “aim,” “goal,” “potential,” “explore” or derivations of such words or similar expressions regarding the future, although forward-looking statements may be denoted by other terms. In this press release, forward-looking statements include those related to Verde’s product potential, commercialization strategy, commercial collaborations, future carbon removal credit generation and monetization, potential CORSIA-related opportunities, and anticipated market demand. These and other statements are based on current expectations and speak only as of the date of this release.

A non-exclusive list of risks and uncertainties that could cause the forward-looking statements herein to differ from future results includes, without limitation: (i) the risk that Verde will not be able to establish definitive licensing or other agreements for Verde or any revenue generating operations, (ii) the risk that Verde and its commercial partners will not be able validate Verde’s plans or gain market acceptance of their products and solutions, (iii) risks that biochar-modified paving materials may not achieve required regulatory or department of transportation approvals, and (iv) risks that field performance of engineered biochar products may differ from laboratory or test results. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include those contained in the Verde’s filings with the SEC, which can be accessed here.

Accordingly, readers are cautioned not to place undue reliance on the forward-looking statements contained herein. Except as required by applicable law, Verde does not plan to publicly update or revise any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise.

For Media and Investors:

Verde Resources, Inc.
info@verderesources.com

C2C Advisors, LLC 

+1-516-295-2111

An image accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c903136a-193a-43bd-82df-9ff3f372de6b

Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference London — Wednesday, November 18, 2026
• Evercore 9th Annual Healthcare Conference — Monday, November 30, 2026
• Citi’s 2026 Global Healthcare Conference — Tuesday, December 1, 2026

Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. 
About Recursion
Recursion (Nasdaq: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York and London, two global hubs for talent and leadership at the intersection of AI and scientific innovation. Learn more at www.recursion.com, or connect on X and LinkedIn.
Media Contact
media@recursion.com
Investor Contact
investor@recursion.com

Joint Campaign Generates Over 8 Million Streams, 75% Spotify and 250% Pandora Audience Growth, Providing a Strong Foundation for Exclusive Marketing Agreement Covering 1,000+ Artists

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — Mobiquity Technologies, Inc. (OTCQB: MOBQ) (“Mobiquity” or the “Company”), a provider of AI-powered customer acquisition and digital marketing technology, today announced impressive results from its joint marketing campaign with Intercept Music, highlighting the significant growth potential of the companies recently established 12-month exclusive digital marketing services agreement.

The campaign, supporting platinum-selling country music duo LOCASH, combined Intercept Music’s artist development and promotional expertise with Mobiquity’s proprietary GrowthOS™ marketing technology, delivering substantial audience growth across major streaming and social media platforms.

More importantly, the successful collaboration provides a foundation for a potentially much larger commercial opportunity: making Mobiquity’s GrowthOS marketing services available to Intercept Music’s network of more than 1,000 artists, creating the potential for meaningful recurring revenue as adoption expands.

Breakout Campaign Demonstrates the Power of GrowthOS

According to the joint campaign case study, key achievements included:

• Over 8 million streams generated during the EP campaign.
• 75% increase in Spotify monthly listeners, from approximately 729,000 to 1.2 million.
• 250% increase in Pandora monthly listeners, from approximately 200,000 to over 700,000.
• More than 20 Spotify editorial playlist additions, contributing to a 12% increase in playlist reach.
• 23% increase in Facebook followers and a 9% increase in TikTok followers.

The campaign also secured prominent playlist placements across Spotify, Apple Music, Amazon Music and Pandora, expanding LOCASH’s exposure to music audiences worldwide.

Campaign Success Shows Path to a Bigger Revenue Opportunity

Under the companies’ exclusive digital marketing services agreement, Mobiquity has been designated Intercept Music’s exclusive digital marketing partner, establishing a commercial framework to offer GrowthOS services throughout Intercept’s growing artist network.

Participating artists are expected to have access to marketing services with anticipated monthly fees generally ranging from $1,000 to $2,000 per artist, plus applicable media and data expenditures.

At just 25% participation across Intercept’s existing roster, representing approximately 250 artists, the relationship would represent a potential $3 million to $6 million in annualized service revenue, assuming continuous participation for 12 months. Additional media and data expenditures would be separate from these service fees.

These figures illustrate the potential scale of the opportunity and are not guaranteed revenue, contracted commitments or management forecasts.

“This is the type of opportunity we built GrowthOS to capture,” said Dean Julia, CEO of Mobiquity Technologies. “The LOCASH campaign demonstrates what our technology can help accomplish when combined with the right industry partner. But the bigger story is what comes next. Rather than building our customer base one artist at a time, we now have an exclusive marketing relationship providing access to a network of more than 1,000 artists. We believe this creates an exciting opportunity to scale our technology, expand our revenue base and build a meaningful recurring-revenue business.”

Julia continued, “What is particularly compelling is that this model is not limited to music. We believe the same approach can be replicated across other industries by partnering with organizations that already have established customer relationships. For Mobiquity and its shareholders, this represents an important step in our transition from a traditional advertising technology provider to a scalable AI-powered customer acquisition company.”

“The campaign results are an exciting example of what our combined capabilities can accomplish,” said Ralph Tashjian, Chairman of Intercept Music. “We have some incredible talent across our roster, including artists such as Maxi Priest, Platinum Catalog featuring John Anderson, Scrimin J Hawkins, Betty Harris, Latin Marcos Manchaca and smooth jazz artist Ron King , who could be among those considered for future joint marketing initiatives. We’re excited about the potential to bring these capabilities to more of our artists and help them connect with audiences in new and meaningful ways.”

About Mobiquity Technologies

Mobiquity Technologies, Inc. (OTCQB: MOBQ) is an innovative AI-powered technology company transforming how businesses identify, engage and acquire customers. Its proprietary, patent-pending GrowthOS™ platform combines advanced audience intelligence, agentic AI-driven decisioning and automated multichannel marketing execution into a unified customer acquisition operating system. Through its technology portfolio and strategic partnerships, Mobiquity is focused on simplifying digital marketing, improving campaign performance and delivering scalable customer acquisition solutions across multiple industries.

For more information, visit www.mobiquitytechnologies.com.

About Intercept Music

Intercept Music is an innovative music technology, distribution and artist services company dedicated to empowering independent artists and record labels worldwide. Supporting a network of more than 1,000 artists, Intercept combines digital distribution, strategic marketing, playlist promotion, artist development and monetization solutions within an integrated platform. Through its relationships with leading streaming services, including Spotify, Apple Music, Amazon Music and Pandora, Intercept helps artists expand their global reach, grow their audiences and maximize revenue opportunities.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding GrowthOS, the Intercept Music agreement, artist participation, anticipated service fees, potential revenue opportunities, business expansion and future performance. These statements involve substantial risks and uncertainties, and actual results may differ materially from those anticipated. Historical campaign results reflect multiple promotional activities and do not guarantee comparable future outcomes. No guarantees can be given regarding future campaign performance, artist participation, revenue generation or the financial success of the relationship. Illustrative revenue scenarios are not forecasts or contractual commitments. Risks include the Company’s limited financial resources, operating losses, liquidity constraints, need for additional financing, potential shareholder dilution, customer adoption, competitive conditions and ability to commercialize its technology and achieve profitability. Failure to obtain sufficient capital could materially affect the Company’s operations and business prospects. Additional risks are described in the Company’s filings with the Securities and Exchange Commission at www.sec.gov. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them except as required by law.

MEDIA CONTACTS:

Mobiquity Technologies
Deep Katyal
info@mobiquitytechnologies.com
516-246-9422

Intercept Music
JC Montes
jc.montes@interceptmusic.com
1-818-749-0029

– Presentations include interim Phase 3 results in women, integrated outcomes from three Phase 3 dialysis access trials and long-term human explant data.

– Podium presentation to provide an update on clinical results with Symvess® in military and civilian trauma settings.

– Company slated to submit Supplemental BLA in AV access for hemodialysis in November.

DURHAM, N.C., Nov. 11, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that its acellular tissue engineered vessel (ATEV) will be featured in five presentations at the 53rd Annual VEITHsymposium, taking place November 17-21, 2026, at the New York Hilton Midtown in New York City. Four abstracts will be presented on Wednesday, November 18, as part of the Associate Faculty program, followed by a podium presentation on Thursday, November 19, on clinical results with Symvess in military and civilian settings.

The VEITHsymposium provides vascular surgeons and other vascular specialists with updates on the most current information about new developments in clinical practice and relevant research. The symposium has over 1,300 presentations on important advancements in the treatment of vascular disease. The ATEV presentations will cover vascular reconstruction in an infected field, interim Phase 3 results in women receiving hemodialysis, integrated durability and safety outcomes across three Phase 3 trials, histologic evidence from explanted vessels, and clinical experience with Symvess in military and civilian vascular trauma.

“Vascular surgeons create dialysis access and repair arteries in some of the most challenging settings, and VEITH puts our data in front of the people who make those decisions. These presentations bring together interim Phase 3 results in women, integrated safety and durability outcomes across three Phase 3 trials, evidence of low atherogenic remodeling from ATEVs that remained in patients long-term, and an update from the trauma surgeons who have used Symvess in military and civilian settings,” said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte.

Presentation Details:

Associate Faculty Program, Session 3: Lower Extremity Arterial – Part 1

• Title: Bioengineered Human Acellular Vessel for Vascular Reconstruction in an Infected Field: A Case Report
• Presenter: Rishi Kundi, M.D., University of Maryland School of Medicine
• Date and time: Wednesday, November 18, 2026, 11:32 AM ET
• Location: Concourse A, Concourse Level, New York Hilton Midtown

Associate Faculty Program, Session 5: Arterial-Venous Access

• Title: Randomized Controlled Trial of Acellular Tissue Engineered Vessel vs. Arteriovenous Fistula for Hemodialysis Access in Females with End-Stage Kidney Disease: Phase 3 CLN-PRO-V012 Interim Analysis
• Presenter: Young Erben, M.D., Mayo Clinic, Jacksonville, Florida
• Date and time: Wednesday, November 18, 2026, 2:22-2:27 PM ET
• Location: Concourse A, Concourse Level, New York Hilton Midtown
• Title: Durability and Safety of Acellular Tissue Engineered Vessels for Hemodialysis Access: Integrated Outcomes from Three Phase 3 Randomized Trials
• Presenter: Mohamad A. Hussain, M.D., Ph.D., Mass General Brigham
• Date and time: Wednesday, November 18, 2026, 2:28-2:33 PM ET
• Location: Concourse A, Concourse Level, New York Hilton Midtown
• Title: Long-Term Human Explant Evidence of Low Atherogenic Remodeling in Acellular Tissue Engineered Blood Vessels (ATEV)
• Presenter: Alexis Lauria, M.D., RPVI, Medical College of Georgia at Augusta University
• Date and time: Wednesday, November 18, 2026, 2:34-2:39 PM ET
• Location: Concourse A, Concourse Level, New York Hilton Midtown

Podium Presentation Session 50

• Title: Update On The Clinical Results And The Future Of A Tissue Engineered Biologic Vascular Conduit (Formerly The Human Acellular Vessel – Now Symvess) In Military And Civilian Settings
• Presenter: Todd E. Rasmussen, M.D., FACS, Mayo Clinic, Rochester, New York
• Date and Time: Thursday, November 19, 2026, 11:50 AM ET
• Location: Grand Ballroom East, 3^rd Floor, New York Hilton Midtown
• Date and time: Thursday, November 19, 2026, 11:50 AM ET

INDICATION

Symvess is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of Symvess integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use Symvess in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. 

WARNINGS AND PRECAUTIONS

• Graft Rupture

Vascular graft rupture has occurred in patients treated with Symvess. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

• Anastomotic Failure

Anastomotic failure has occurred in patients treated with Symvess. In clinical studies of Symvess, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

• Thrombosis

Thrombosis has occurred in patients treated with Symvess. In clinical trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with Symvess.

• Transmission of Infectious Diseases

Symvess is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of Symvess are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum). The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and pain.

Please see full Prescribing Information at www.symvess.com, including Boxed Warning, for Symvess.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended September 30, 2026, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

MONTRÉAL, Nov. 11, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V: FPC) (“Falco” or the “Corporation”) reports substantial progress on Falco’s Horne 5 Project (the “Horne 5 Project” or “Project”) since the Bureau d’audiences publiques sur l’environnement (“BAPE”) report. Working with Québec’s Ministry of the Environment, the Fight Against Climate Change, Wildlife and Parks (“MELCCFP”), Falco has advanced technical and environmental assessments, addressed community concerns and made tangible regional commitments. This update highlights the progress made in addressing concerns and advancing the Horne 5 Project toward the next stages of its development.

Advancing toward a key environmental milestone
Hélène Cartier, Vice-President, Environment, Sustainable Development and Community Relations at Falco, commented: “The past two years have been an important phase in the development of the Horne 5 Project. This time has enabled us to better understand community concerns, further assess several technical, social and environmental aspects, and strengthen our commitments. The progress achieved puts us in a position to continue advancing toward a major milestone: obtaining the environmental decree.”

Continued progress with Québec’s Ministry of the Environment and the New Government
In June 2026, the MELCCFP indicated that information submitted by Falco allowed potential solutions to be identified for issues raised during the review. At that time, the Ministry anticipated completing its environmental acceptability assessment in fall 2026, subject to receiving satisfactory additional information.

Falco continues to participate in working sessions with the Ministry’s Environmental Assessment Directorate and to respond to requests for clarification and supporting information. Meanwhile, the Corporation is engaging with members of the new government following last October’s elections.

Concrete commitments to the community
Alongside the environmental review, Falco has advanced a series of initiatives focused on community dialogue, protection of residences and infrastructure, quality of life and lasting regional benefits. Since January 2025, these initiatives have included:

Community dialogue and accountability

• Ten meetings of the Advisory Committee, including its Integrity, Residences and Infrastructure subcommittee, bringing together diverse community representatives and, where appropriate, independent experts. – See the 2025 Activity Report (French). Note: Meeting minutes are available through the Horne 5 Project’s documentation (French).
• A community engagement governance framework developed with Rouyn-Noranda-based Agence Marinade to support structured, ongoing dialogue.
• An initial Integrity – Residences and Infrastructure Program addressing vibration-related commitments, together with a Community Interaction Management Plan (French).
• An independent Léger survey on understanding and social acceptability of the Horne 5 Project (French).

Regional economic and quality-of-life assessments and benefits

• Aviseo Consulting’s Socioeconomic study examining how an influx of workers could affect demand for services in Rouyn-Noranda (French).
• An updated 2026 economic impact assessment prepared by KPMG (French).

Addressing vibration-related concerns

• An independent expert report issued in March 2026 commissioned by the Regional Public Health Department (CISSS-AT) concluded that Falco’s mining activities could proceed without significant risk to the equipment at the Rouyn-Noranda Radiation Oncology Centre (the “Centre”), provided specified measures are implemented.
• Falco conducted continuous vibration monitoring at the Centre from February through September 2026 to assess existing conditions and how vibrations attenuate through the ground.

Investing in community projects

• A consultation table established with the City of Rouyn-Noranda to discuss a framework contribution agreement.
• A three-year, $90,000 partnership with Collectif Territoire supporting rehabilitation of lac Osisko (French).
• A workplan with the City of Rouyn-Noranda to acquire the Arthur-Gagnon ecocentre lands (French).
• A Contribution toward construction of a new ecocentre on Mathieu Street in the industrial district (French).

Luc Lessard, President and Chief Executive Officer of Falco Resources, added: “The Horne 5 Project has the potential to deliver lasting economic benefits to Rouyn-Noranda and the wider region. Our progress is measured not only by technical milestones, but also by how we respond to local priorities. We are advancing the Project through sustained dialogue, independent assessment and concrete commitments to the community.

Next Milestone: the environmental decree
Falco is working with the MELCCFP to complete the environmental assessment. Once that assessment concludes, the MELCCFP then recommend the Project to the Québec Cabinet, which will determine whether to authorize it by decree. The decree would mark a major milestone, allowing Falco to move forward with detailed engineering and preparatory development work. Additional studies, permits and authorizations would still be required before construction and operations.

A significant opportunity for Rouyn-Noranda and the region
The Horne 5 Project represents approximately $1.75 billion in planned investment and the potential for 500 direct, permanent jobs. An independent KPMG assessment (French) estimates $12.1 billion in project-related expenditures over 15 years, with the potential to support economic activity across Rouyn-Noranda and the Abitibi-Témiscamingue.

Based on its current project schedule, Falco is targeting receipt of the environmental decree in early 2027. The timing and outcome remain subject to the government’s assessment and authorization process.

For more information about the Corporation and its project:

• Falco Resources: Home | Ressources Falco
• Falco Horne 5 Project (French): Home | Falco Horne 5

About Falco
Falco is one of the largest mineral claim holders in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp, which includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:
Luc Lessard	Stéphane Gasse
President and Chief Executive Officer and Director	National Public Relations
	sgasse@national.ca
Hélène Cartier	(418) 265-8056
Vice-president
Environment, Sustainable Development and Community Relations

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are typically identified by words such as: “believe”, “envisions”, “estimates”, “assumes”, “evaluates”, “inferred”, “probability”, “planned”, “projected”, “ensure” “anticipates”, “contemplated”, “expected”, “anticipate” and similar expressions, or that events or conditions “would”, “will”, “can”, or may” occur. All statements that are not statements of historical fact are forward-looking statements.

Forward-looking statements in this press release include, without limitation, statements regarding the projections and assumptions of the Report, including, without limitation: expected direct and indirect Québec and regional GDP contribution from the Project; expected federal, provincial and local tax revenue; and economic assumptions and sensitivities and other operational and economic projections with respect to the Horne 5 Project as well as benefits of the Project for the community.

Although the Corporation believes the forward-looking statements in this press release are reasonable, it can give no assurance that the expectations and assumptions in such statements will prove to be correct. Consequently, the Corporation cautions investors that any forward-looking statements by the Corporation are not guarantees of future results or performance and that actual results may differ materially from those in forward-looking statements.

The forward-looking statements contained herein is subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements, including, without limitation: the effects of general economic conditions; changing foreign exchange rates; risks associated with exploration and project development; the calculation of mineral resources and reserves; risks related to fluctuations in metal prices; uncertainties related to raising sufficient financing to fund the planned work in a timely manner and on acceptable terms; changes in planned work arising from weather, logistical, technical or other factors; the possibility that results of work will not fulfill expectations and realize the perceived potential of the Corporation’s properties; risk of accidents, equipment breakdowns and labour disputes; access to project funding or other unanticipated difficulties or interruptions; the possibility of cost overruns or unanticipated expenses in the work program; title matters; government regulation; obtaining and receiving necessary licenses; the risk of environmental contamination or damage resulting from Falco’s operations, the risk that the conditions precedent to the ability to conduct dewatering or mining activities under the operating license and indemnity agreement (“OLIA”) dated January 23, 2024 between Falco and Glencore Canada Corporation (“Glencore”) may not be satisfied; the risk that Falco may not obtain the required financial assurances to be provided to Glencore, or the financing required to develop or operate the Horne 5 Project; the risk that the required permits and authorizations required from governmental authorities to develop and operate the Horne 5 Project may not be obtained on the terms contemplated or at all; the risk that the OLIA may be terminated in accordance with its terms in the event of default or certain other triggers relating to delays in the commencement of dewatering or mining activities; the risk that, once commenced, certain operations of the Horne 5 Project may have to be suspended, altered or modified pursuant to the conditions of the OLIA; the risk that Glencore may require modifications to Falco’s operations at the Horne 5 Project pursuant to the OLIA which would render the operations less profitable or not profitable (compared to expectations included in the 2026 Feasibility Study); the risk that Falco may incur significant losses and other obligations under its indemnities in favour of Glencore contemplated in the OLIA; and other risks and uncertainties including those described in the Corporation’s Management’s Discussion & Analysis for the year ended June 30, 2026, dated September 30, 2026 available at www.sedarplus.ca.

The forward-looking statements contained in this news release are based on the beliefs, estimates and opinions of Falco’s management on the date the statements are made. Although Falco has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Corporation is under no obligation to update or alter any forward-looking statements except as required under applicable securities laws.

Call Scheduled for 8:00 am ET on Thursday, November 12, 2026

NEW YORK, Nov. 11, 2026 (GLOBE NEWSWIRE) — BCP Investment Corporation (NASDAQ: BCIC) (“BCIC” or “the Company”) today announced the release of its financial results for the third quarter ended September 30, 2026, is scheduled for today, Wednesday, November 11, 2026, after market close. The Company will host a conference call on Thursday, November 12, 2026 at 8:00 a.m. ET to discuss these results.

By Phone: To access the call, please dial (646) 307-1963 approximately 10 minutes prior to the start of the conference call and use the conference ID 2135550.

A replay of this conference call will be available shortly after the live call through November 19, 2026.

By Webcast: A live audio webcast of the conference call can be accessed via the Internet, on a listen-only basis at https://edge.media-server.com/mmc/p/ykee8aoy. The online archive of the webcast will be available on the Company’s website shortly after the call at www.bcpinvestmentcorporation.com in the Investor Relations section under Events and Presentations.

About BCP Investment Corporation
BCP Investment Corporation (Nasdaq: BCIC) is a publicly traded, externally managed closed-end investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940. BCIC’s middle market investment business originates, structures, finances and manages a portfolio of term loans, mezzanine investments and selected equity securities in middle market companies. BCIC’s investment activities are managed by its investment adviser, Sierra Crest Investment Management LLC, an affiliate of BC Partners Advisors L.P.

BCIC’s filings with the Securities and Exchange Commission, earnings releases, press releases and other financial, operational and governance information are available on BCIC’s website at www.bcpinvestmentcorporation.com.

Contacts:

BCP Investment Corporation

650 Madison Avenue, 3rd floor
New York, NY 10022
info@bcpinvestmentcorporation.com

Brandon Satoren
Chief Financial Officer
Brandon.Satoren@bcpartners.com
(212) 891-2880

The Equity Group Inc.
Lena Cati
lena.cati@theequitygroup.com
(212) 836-9611

The Equity Group Inc.
Val Ferraro
val.ferraro@theequitygroup.com
(212) 836-9633

On-demand delivery API to enable builders, businesses and AI assistants to develop new delivery services on Serve’s fleet of 2,000 robots across more than 150 U.S. neighborhoods

SAN FRANCISCO, Nov. 11, 2026 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leading physical AI company, today launched the AV Delivery Developer Portal, which for the first time gives anyone, from independent developers and hobbyists, to businesses and AI assistants, the opportunity to programmatically summon robots from Serve’s autonomous sidewalk delivery fleet. The launch includes a public API, a connection that allows new applications and businesses to work with Serve’s fleet of sidewalk robots, and a sandbox environment where anyone can build and test before using a live robot.

On November 5, Serve opened the technology behind its robots to companies building new types of robots with the launch of Serve Physical AI Services. Today, it opens the fleet itself to anyone needing affordable and efficient autonomous last-mile delivery.

Serve’s robots have completed hundreds of thousands of deliveries across more than 150 neighborhoods in 20 US cities, where until now they’ve only been available through third-party delivery partners. With today’s launch, anyone can dispatch those robots with a few lines of code, even through an AI assistant. The same robots previously only available through the largest delivery platforms can now power any local delivery.

“You shouldn’t have to start a robotics company to build something useful with robots,” said Ali Kashani, Co-Founder and CEO of Serve Robotics. “We’ve spent years figuring out how robots can navigate neighborhoods. The people who live and work there will have needs we haven’t thought of. Opening our fleet gives us an opportunity to serve those needs.”

Serve’s robots exist to take the drudgery out of everyday errands and make on-demand delivery affordable for everyone. Businesses can use robots to transport goods between their offices. Merchants can bring their shelves to the front door of customers. Local businesses can expand their delivery footprint without hiring new staff. Developers can build these moments into their existing apps, businesses can wire robots into their daily workflows, and AI assistants can carry out tasks in the physical world for the first time.

Building on the fleet works like building on any other API. An application or AI assistant requests a pickup and dropoff, confirms the details, and tracks the robot until the delivery is complete. Serve handles robots’ dispatch, routing, navigation and supervision, making sure a timely and reliable delivery. The sandbox, with simulated robots, lets builders run the full delivery workflow and rehearse edge cases before touching a real robot.

Builders can explore the documentation and sandbox today at https://developer.serverobotics.com. Access to live robots is subject to Serve’s approval. Those who wish to move beyond the sandbox can indicate their interest via the portal.

Robots dispatched through the API are subject to the same operating standards as every Serve delivery, including remote monitoring by trained supervisors and the safety systems built into each vehicle. Deliveries are limited to Serve’s active service areas and operating hours, and to items that fit within the robot’s cargo compartment.

About Serve Robotics

Serve Robotics (Nasdaq: SERV) designs and operates autonomous robots that navigate complex, human-centric environments. Since spinning off from Uber in 2021, Serve has deployed more than 2,000 robots across the U.S. and Australia, reaching a population of approximately 3 million and supporting delivery for more than 4,000 restaurants. In 2026, Serve acquired Diligent Robotics, expanding its operations beyond sidewalk delivery into indoor service robots used in hospitals. Serve designs both the hardware and software behind its robots, enabling them to work safely in public and private environments at scale.

For more information, visit www.serverobotics.com or follow the company on X, Instagram, and LinkedIn @serverobotics.

Forward Looking Statements
This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when we or our management are discussing our beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “may,” “could,” “should,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance, but represent management’s belief at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside of our control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements.

The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those described in our filings with the Securities and Exchange Commission (“SEC”), including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by those risks and uncertainties described in the Company’s subsequent SEC filings. The Company can give no assurance that the plans, intentions, expectations or strategies as reflected in or suggested by those forward-looking statements will be attained or achieved. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contacts
Media
press@serverobotics.com

Investor Relations
investor.relations@serverobotics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e1f91c66-a285-43f7-a1dd-44ff32366130

New fourth-quarter clients, strategic partnerships and additional payer audit successes strengthen CareCloud’s position in the multibillion-dollar wound care market

SOMERSET, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) — CareCloud, Inc. (Nasdaq: CCLD) (“CareCloud” or the “Company”), a leader in AI-powered healthcare technology and revenue cycle management (“RCM”) solutions, today announced accelerating momentum in the wound care market, driven by new fourth-quarter clients, strategic partnerships, a new bi-directional EHR integration and multimillion-dollar payer audit successes through Empower Healthcare & Compliance Inc. (“Empower”), its healthcare compliance division.

New Clients and Strategic Partnerships
CareCloud signed multiple new wound care clients during the fourth quarter and was selected as a preferred vendor by Vantage Health Collective, a multi-specialty management services organization (“MSO”), initially supporting three practices in Texas, Northern Florida and California.

CareCloud also launched a bi-directional EHR interface that enables wound care practices to adopt its RCM and compliance services without replacing their existing EHR systems. A mobile wound care practice was the first to go live on the integration, through a relationship developed with Kindling Consulting, demonstrating an additional channel for expanding CareCloud’s presence in the specialty.

Multimillion-Dollar Payer Audit Successes
Empower recently supported a wound care provider represented by healthcare law firm Frier Levitt in successfully appealing approximately $3 million in alleged Medicare overpayments involving skin substitute grafts. This builds on Empower’s previously announced success in helping another wound care provider overturn more than $1 million in alleged overpayments following an administrative law judge appeal.

Together, these cases demonstrate Empower’s specialized coding, documentation and compliance capabilities and strengthen CareCloud’s differentiated offering for wound care providers.

Expanding in a Multibillion-Dollar Market
Medicare wound care spending was estimated at $22.5 billion in 2019, according to a 2023 study published in the Journal of Medical Economics, and Medicare skin substitute spending was projected to reach $15.4 billion in 2025, according to the National Association of ACOs. Increasing reimbursement complexity and payer scrutiny are driving demand for specialized RCM and compliance solutions.

“Wound care represents a significant growth opportunity for CareCloud,” said Stephen Snyder, Chief Executive Officer of CareCloud. “We are winning new clients, expanding strategic relationships and integrating with existing EHR platforms. Combined with Empower’s proven compliance expertise, we believe CareCloud is well positioned to help wound care providers improve collections, defend legitimate reimbursements and navigate an increasingly complex regulatory environment.”

CareCloud intends to expand its wound care business through additional client relationships, EHR integrations and partnerships with specialty practices and MSOs.

About CareCloud
CareCloud brings disciplined innovation to the business of healthcare. The Company’s suite of AI and technology-enabled solutions helps healthcare organizations increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers rely on CareCloud’s solutions and services across revenue cycle management, practice management, electronic health records, patient experience management, business intelligence and digital health.

Follow CareCloud on LinkedIn, X and Facebook.

For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.

Forward-Looking Statements
This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could”, “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, expectations regarding growth in wound care, expansion of client and MSO relationships, adoption and expected benefits of the new EHR interface, anticipated practice implementations, demand for compliance and revenue cycle services, and opportunities to deepen relationships and win additional business. Past operational or stock price performance is not an indication of future performance. Past outcomes of payer audits and appeals are not a guarantee of results in any future matter. The Company does not expect the new client agreements described in this release to have a material impact on its financial results.

These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies’ products and services competitive with ours, and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE: CareCloud

Company Contact:
Bonnie Boyer
Chief Financial Officer
CareCloud, Inc.
bboyer@carecloud.com

Investor Contact:
Stephen Snyder
Chief Executive Officer
CareCloud, Inc.
ir@carecloud.com

Appointment brings leadership experience building and financing biopharma companies

AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) — Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Jill M. Quigley to its Board of Directors (the “Board”). Ms. Quigley brings additional executive leadership experience to Filana, having previously scaled biopharma companies through pivotal stages of drug development, financing, and value creation.

“On behalf of the Board, I welcome Jill to Filana. Her record of guiding companies through financings and strategic growth will broaden the expertise around our Board table,” commented Claude Nicaise, MD, Chairman of the Board of Filana Therapeutics. “This appointment reflects our continued focus on aligning the Board with Filana Therapeutics’ evolving needs as the Company moves simufilam through clinical development.”

“Jill joins Filana at an exciting time, as we prepare for our planned Phase 2a clinical study of simufilam in TSC-related epilepsy, with patient screening expected to begin by the first quarter of 2027,” said Rick Barry, President and Chief Executive Officer of Filana Therapeutics, Inc. “We believe in the scientific rationale supporting our program in TSC, and I look forward to collaborating closely with Jill as we work to create value for patients, their families, and shareholders.”

Jill M. Quigley, Independent Director of Filana Therapeutics, added, “I am pleased to join the Filana Therapeutics Board and eager to contribute my experience as the Company advances simufilam through clinical development. I have been particularly impressed by Filana’s commitment to patients and its science-driven approach to developing a potential new treatment for TSC-related epilepsy.”

About Jill M. Quigley

Jill Quigley brings more than 20 years of biotechnology industry leadership experience to Filana. Her prior work encompasses executive management, corporate operations, legal affairs, financing, and board membership. Building on her initial expertise in legal affairs, she has broadened her capabilities and experience, ultimately serving as head of operations and chief executive of biotechnology firms developing innovative products for rare diseases.

Ms. Quigley has worked extensively with public and private biotechnology companies, established domestic and international operations, and helped lead major financing rounds. She is currently the CEO of a preclinical biotechnology company since November 2026 and recently served as Entrepreneur in Residence at J.P. Morgan Life Sciences Private Capital from November 2025 to November 2026. She served on the board of directors of Terns Pharmaceuticals, Inc. (formerly NASDAQ: TERN) from December 2020 until its acquisition by Merck in May 2026, where she also served as a senior advisor and strategy officer on an interim basis from October 2023 through February 2024. Ms. Quigley served on the board of Chemomab Therapeutics Ltd. (NASDAQ: CMMB) from 2022 to 2026.

Previously, Ms. Quigley was the Chief Executive Officer of Genuiti Therapeutics, Inc. from September 2023 through June 2025. Prior to that, Ms. Quigley was Chief Operating Officer at Passage Bio, Inc., a publicly traded gene therapy company, from November 2018 to December 2021, and before that she served as Chief Executive Officer and General Counsel of Nutrinia, Ltd., a developer of treatments for rare gastrointestinal diseases.

Earlier in her career, Ms. Quigley was Senior Counsel at NPS Pharmaceuticals, Inc., a publicly traded biotechnology company that was acquired by Shire plc; served as Corporate Counsel for Pharmasset, Inc., a publicly traded biotechnology firm acquired by Gilead Sciences, Inc.; and served as Assistant Corporate Counsel for publicly traded Integra LifeSciences Holdings Corporation.

Ms. Quigley practiced as an Associate with the law firm Dechert LLP. She holds a BA degree from American University and a JD from Rutgers School of Law.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (NASDAQ: FLNA) is a biotechnology company focused on developing novel therapies to modulate filamin A for the treatment of central nervous system (CNS) disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

For more information, please visit: https://www.FilanaTx.com

For More Information Contact:
Investors
Mike Moyer
mmoyer@lifesciadvisors.com

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@FilanaTx.com
IR@FilanaTx.com

Cautionary Note Regarding Forward-Looking Statements:

This news release contains forward-looking statements that may include but are not limited to statements regarding: the anticipated contributions of Ms. Quigley to the Board and the Company; the timing and plans to initiate and conduct clinical studies with simufilam in TSC-related epilepsy; the design, structure, duration, objectives, endpoints, patient population, conduct, enrollment, completion, and potential results of our planned Phase 2a clinical trial; our ability to work with clinical investigators and the TSC community to advance the trial efficiently; the potential for simufilam as a treatment for TSC-related epilepsy and other potential indications; our ability to create value for patients, their families and stockholders; and the timing of anticipated milestones. These statements may be identified by words such as “anticipate”, “before”, “believe”, “could”, “expect”, “forecast”, “intend”, “look forward”, “may”, “pending”, “plan”, “possible”, “potential”, “prepare”, “will”, and other words and terms of similar meaning.

Such statements are based on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to our ability to initiate, enroll, conduct, and complete the planned Phase 2a study of simufilam in TSC-related epilepsy; our ability to engage clinical trial sites and participants; our ability to work effectively with clinical research organizations, vendors, investigators, patient advocacy organizations, and the TSC community; the expected impact of new members of the Board of Directors, and other risks inherent in drug discovery and development or specific to Filana Therapeutics, Inc., as described in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, Form 10-Q for the quarter ended September 30, 2026 and subsequent reports filed or to be filed with the U.S. Securities and Exchange Commission (SEC). The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.

All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.

EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• Stifel NYC Healthcare Conference (New York, November 10–12, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on Thursday, November 12 from 1:20 PM to 1:50 PM EST. BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
• UBS Global Biopharma Conference (London, November 16–17, 2026): BJ Sullivan, PhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on Monday, November 16 from 11:40 AM to 12:10 PM EST. BJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. To access the live audio webcast of the presentation, register here.
• Jefferies London Healthcare Conference (London, November 16–19, 2026): Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, November 19 from 6:00 AM to 6:25 AM EST. Kristen Fortney, Dov Goldstein, MD, CFO, BJ Sullivan, PhD, Chief Strategy Officer, and Alexis Jakubowski, Associate Director, Strategy & Investor Relations, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the presentations will be available in the investor section of the Company’s website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the biology of human aging. The Company’s lead product candidate, BGE-102, is a potent, orally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being developed for diseases driven by inflammation, including diabetic macular edema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular proof-of-concept data from QUELL-CV are anticipated in the fourth quarter of 2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated in the second half of 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com